Recursion Pharmaceuticals (RXRX) Leerink Global Healthcare Conference 2026 summary

Strategic focus and portfolio management

• Emphasis on three strategic areas: doubling down on proof points, targeted platform investment, and disciplined ambition.

• Rapid go/no-go decisions are made across programs, with a data-driven approach to portfolio management.

• Joint portfolio with Sanofi includes five programs targeting challenging I&I and oncology targets.

• Platform efficiency improvements allow for 90% fewer compounds synthesized and faster clinic advancement compared to industry standards.

• Outcomes-based budgeting aligns capital allocation with milestone achievement and conviction in data.

Financial guidance and capital allocation

• Annual guidance is provided, with significant updates tied to strategic changes; 2026 gross burn expected to be under $390 million, excluding partnership inflows.

• Partnership milestones are expected to provide meaningful non-dilutive capital.

• Portfolio management approach allows for dynamic reallocation of resources based on program progress.

• Opportunistic use of ATM has extended runway into early 2028.

• Focus on building a strong shareholder base and attracting biotech investors as more data becomes available.

Partnerships and competitive landscape

• Value realization from partnerships is prioritized over announcements, with over $500 million in upfront and milestones received.

• Roche and Sanofi partnerships highlight differentiated, vertically integrated AI tech stack and wet/dry lab capabilities.

• Sanofi partnership offers up to $343 million per program in milestones, with significant pre-commercial payouts and low double-digit royalties.

• Up to 15 programs possible with Sanofi and up to 40 with Roche, providing substantial growth runway.

• Partnerships structured to cover direct costs and build platform value without using internal capital.